Home > Riviste > Panminerva Medica > Fascicoli precedenti > Articles online first > Panminerva Medica 2020 May 14

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

 

Panminerva Medica 2020 May 14

DOI: 10.23736/S0031-0808.20.03931-2

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Efficacy of conversion surgery on stage IV gastric cancer and its prognosis analysis

Zhilong ZHAO 1 , Yi FAN 1, Yu SUN 1, Fang XU 2, Shen SHEN 1

1 Department of General Surgery, The Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, China; 2 Department of Anesthesiology, The Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, China


PDF


BACKGROUND: To explore the clinical efficacy and safety of conversion surgery in the treatment of stage IV gastric cancer, and to analyze the influencing factors for the prognosis of patients.
METHODS: The clinical data of 84 patients with stage IV gastric cancer treated in our hospital from September 2014 to March 2016 were collected. All patients were treated with S-1 + oxaliplatin or S-1 + docetaxel chemotherapy, among which 42 patients had surgical indications after chemotherapy and received gastrectomy (R0 resection or R1 resection) (conversion surgery group), and the remaining 42 patients had no surgical indications after chemotherapy (simple chemotherapy group). The patients in both groups were followed up to record the survival status, and the possible influencing factors for the prognosis were analyzed.
RESULTS: In conversion surgery group, the median chemotherapy cycle was 4.3, and the objective response rate (ORR) was 73.8% (31/42). During chemotherapy in the two groups, there were 22 cases (52.3%) and 24 cases (57.1%) of hematological toxicity, and 28 cases (66.7%) and 32 cases (76.2%) of non-hematological toxicity, mainly in grade I-II, which could be relieved after symptomatic treatment, and chemotherapy was successfully completed. After chemotherapy, 42 out of 84 patients met the surgical indications. All patients were followed up for 6-36 months. The 3-year overall survival was 35.7% (15/42) and 9.5% (4/42), respectively, in the two groups, and the difference was statistically significant according to the log-rank test (P<0.05). The results of multivariate analysis showed that whether the surgical margin was R0 was an independent influencing factor for the prognosis of patients (HR=8.012, 95% CI=2.522-14.384, P=0.027).
CONCLUSIONS: Radical surgery after conversion therapy can raise the survival rate of patients, with tolerable adverse reactions. Whether the surgical margin is R0 in conversion therapy is an independent influencing factor for the prognosis of patients with stage IV gastric cancer.


KEY WORDS: Gastric cancer; Stage IV; Conversion therapy; Surgery; Chemotherapy; Prognosis

inizio pagina